(Q46205747)
Statements
1 reference
Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration (English)
1 reference
Allen C Ho
1 reference
Brandon G Busbee
1 reference
Carl D Regillo
1 reference
Mark R Wieland
1 reference
Sherri A Van Everen
1 reference
Zhengrong Li
1 reference
Roman G Rubio
1 reference
Phillip Lai
1 reference
HARBOR Study Group
1 reference
9 July 2014
1 reference
1 reference
121
1 reference
11
1 reference
2181-2192
1 reference